Sivelestat for neuromyelitis optica spectrum disorder relapses
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests a drug called sivelestat for people with neuromyelitis optica spectrum disorder (NMOSD) who are having a relapse. The drug may help reduce damage during the relapse and improve recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of NMOSD and test positive for the AQP4 antibody.
- You must be having a relapse now (within the last 14 days) that affects your vision or spinal cord, and it must be severe enough to be measured on a disability scale.
- You must be 18 years or older.
- You cannot have received more than one round of steroid pulse therapy, or any plasmapheresis or high-dose immunoglobulin for this current relapse.
- You must be willing to use contraception if you or your partner could become pregnant, during the study and for a period after.
- You should not have other serious health conditions like severe lung disease, severe liver disease, or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at treatments for people with neuromyelitis optica spectrum disorder (NMOSD) who are having a sudden attack affecting their vision or spinal cord. It aims to find out which treatments work best in everyday practice.
This trial tests a new antibody-based medicine to help people recover from an acute attack of neuromyelitis optica spectrum disorder (NMOSD), a condition that causes inflammation in the eyes and spinal cord. If you are having a recent flare-up and are already getting or planning to get steroid treatment, this study might offer an additional option to reduce damage and speed recovery.
This trial tests a new medicine (NouvSoma001) for people with neuromyelitis optica (NMOSD) who are having a flare-up. The goal is to see if the treatment is safe and if it helps reduce symptoms like pain and trouble moving.
This trial tests whether an investigational drug called KSVCBD can safely reduce relapses in people with neuromyelitis optica spectrum disorder (NMOSD). If you have had at least one relapse in the past year and meet other criteria, you may be able to join.
This trial tests a new stem cell treatment for people with a severe relapse of neuromyelitis optica (NMO), a rare autoimmune disease that affects the eyes and spinal cord. The treatment may help reduce damage and improve recovery.
This study looks at how well satralizumab works in people with NMOSD (a rare disorder that affects the nerves in your eyes and spine). It is for people who have had recent flare-ups and test positive for a specific antibody (AQP4). You will receive satralizumab and be followed for at least one year to see if your disease stays under control.
Hear when a new Neuromyelitis Optica Spectrum Disorder Attack trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.